1EsserN,PaquotN,ScheenAJ.Type 2 diabetes and anti-inflammatory agents: new therapeutic prospects ?[J].Rev Med Suisse,2011,7(306):1614-1618,1620.
2WinklerK,HoffmannMM,WinkelmannBR,et al.Lipoprotein-associated phospholipase A2 predicts 5-year cardiac mortality independently of established risk factors and adds prognostic information in patients with low and medium high-sensitivity C-reactive protein(the Ludwigshafen risk and cardiovascular health study)[J].Clin Chem,2007,53(8):1440-1447.
3MallatZ,LambeauG,TedguiA.Lipoprotein-associated and secreted phospholipases A2 in cardiovascular disease: roles as biological effectors and biomarkers[J].Circulation,2010,122(21):2183-2200.
4KudoloGB,BresslerP,DeFronzoRA.Plasma PAF acetylhydrolase in non-insulin dependent diabetes mellitus and obesity: effect of hyperinsulinemia and lovastatin treatment[J].J Lipid Mediat Cell Signal,1997,17(2):97-113.
5BasuA,JensenMD,McCannF,et al.Lack of an effect of pioglitazone or glipizide on lipoprotein-associated phospholipase A2 in type 2 diabetes[J].Endocr Pract,2007,13(2):147-152.
6FortunatoJ,BláhaV,BisJ,et al.Lipoprotein-associated phospholipase A2 mass level is increased in elderly subjects with type 2 diabetes mellitus[J].J Diabetes Res,2014,2014:278063.
7VlachojannisGJ,Scholz-PedrettiK,FierlbeckW,et al.Enhanced expression of group IIA secreted phospholipase A2 by elevated glucose levels in cytokine-stimulated rat mesangial cells and in kidneys of diabetic rats[J].Clin Nephrol,2005,63(5):356-367.
8NelsonTL,BiggsML,KizerJR,et al.Lipoprotein-associated phospholipase A2(Lp-PLA2)and future risk of type 2 diabetes: results from the Cardiovascular Health Study[J].J Clin Endocrinol Metab,2012,97(5):1695-1701.
9KonukogluD,UzunH,FirtinaS,et al.Plasma adhesion and inflammation markers: asymmetrical dimethyl-L-arginine and secretory phospholipase A2 concentrations before and after laparoscopic gastric banding in morbidly obese patients[J].Obes Surg,2007,17(5):672-678.
